Recent Updates
Recently added Catalysts
DMAC Positive Sentiment

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

Wednesday, September 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: DiaMedica Therapeutics Inc. will participate in four investor conferences in New York, including the Citi Biopharma Back to School Summit and the Cantor Global Healthcare Conference. The company's management, including CEO Rick Pauls, will engage with investors to discuss their clinical-stage biopharmaceutical developments. This participation highlights DiaMedica's commitment to advancing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.

Market Sentiment Analysis

POSITIVE FACTORS

  • DiaMedica is actively participating in multiple investor conferences.
  • The company is focused on developing novel treatments for serious conditions.
  • Management's engagement with investors indicates strong confidence in their pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~15 mo
Low dilution risk
Lead asset
Recombinant human tissue kallikrein
Phase 2 · Acute Ischemic Stroke

Full Press Release Details

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York. Details Citi Biopharma Back to School Summit September 9-10, 2026 Cantor Global Healthcare Conference September 9-11, 2026 Fireside Chat with Rick Pauls (CEO)

Frequently Asked Questions

What conferences will DiaMedica attend?

DiaMedica will participate in the Citi Biopharma Back to School Summit and the Cantor Global Healthcare Conference.

Who will represent DiaMedica at the conferences?

CEO Rick Pauls and other management will represent DiaMedica at the investor conferences.

What is DiaMedica focused on developing?

DiaMedica is focused on developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.

When are the investor conferences scheduled?

The investor conferences are scheduled for September 9-11, 2026.

ShareAdd on Google
Tags: DMAC Viatris Investor Conferences Healthcare DiaMedica investor conferences biopharmaceuticals preeclampsia
Last updated: Sep 2, 2026

Biotech snapshot

Cash runway
$44M liquidity · $3M/mo burn
~15 mo
Low dilution risk
Lead asset
Recombinant human tissue kallikreinPhase 2
Acute Ischemic Stroke →